Page last updated: 2024-11-05

trazodone and Atrophy

trazodone has been researched along with Atrophy in 1 studies

Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.

Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nguyen, M1
Myers, WC1

Other Studies

1 other study available for trazodone and Atrophy

ArticleYear
Trazodone for symptoms of frontal lobe atrophy.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2000, Volume: 39, Issue:10

    Topics: Adolescent; Aggression; Atrophy; Attention Deficit Disorder with Hyperactivity; Child; Dementia; Fet

2000